Pricing/Valuation | CRMD Message Board Posts


CRMD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  47577 of 47891  at  8/15/2022 11:39:47 PM  by

mrices1.1

The following message was updated on 8/15/2022 11:42:26 PM.

 In response to msg 47562 by  ChazCSP
view thread

Re: Pricing/Valuation

 
 Chaz
This is a great financial model !  Detailed assumptions that 3 years later still seem realistic and very positive in terms of growing market cap/pps.  CRMD should be able to put together a strong value prop well north of $15/vial in HD, and In-Patient should be a lot higher than HD, making a strong story that much stronger. 
 
Another point to be considered - unlike a number of biotechs that have to continue to invest huge $s in R&D, while they build over-staffed senior mngt teams and extensive sales infrastructure, CRMD should be able to get this product on the market and start turning a profit relatively quickly with reasonable SG&A and modest R&D -
 
Also, there's high probability Oncology will be approved , more than doubling HD and In-Patient revenue.  By that point we will likely have been sold, but I hope/believ at a very big multiple of current pps.  Don't want to sound like a cheerleader as I know how long this has taken, but hopefully it will be worth it.
 

 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 10  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
47578 Re: Pricing/Valuation fmrick 12 8/16/2022 9:12:09 AM




Financial Market Data provided by
.
Loading...